Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 4,249 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
Interventions: CSP01, Carboxymethylcellulose (CMC), Placebo; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 22 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions: Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Cypress, California • Glendale, California • Denver, Colorado + 4 more

Conditions: Preterm Delivery
Interventions: Betamethasone or Dexamethasone (2nd course of ACS), Placebo; Drug
Lead sponsor: Obstetrix Medical Group; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 16 more

Conditions: Postural Tachycardia Syndrome
Interventions: pyridostigmine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 15 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pregnancy, Preeclampsia (PE)
Interventions: 17 OHPC; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Pain
Interventions: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%), Placebo Peel; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Binge Eating Disorder
Interventions: dasotraline 4mg, dasotraline 6mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Phoenix, Arizona • Beverly Hills, California • Encino, California + 44 more

Conditions: Retinal Disease
Interventions: IRX-101, Providone-Iodine; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atopic Dermatitis, Type 1 Hypersensitivity
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 0 Days to 14 Days
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection); Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Drug-Coated Device, Control Device; Device
Lead sponsor: Intersect ENT; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: entinostat, avelumab, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Tampa, Florida • West Palm Beach, Florida • Chicago, Illinois + 7 more

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: RYZ811, RYZ801; Diagnostic Test · Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 10 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: TERN-201, Placebo; Drug · Other
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more

Conditions: Chronic Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 49 more

Conditions: PTSD
Interventions: TNX-102 SL, Placebo SL Tablets; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Cocaine Use Disorder
Interventions: EMB-001, Placebo, Cocaine IV, Saline IV; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Gout
Interventions: High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more

Conditions: Hyperuricemia, Gout
Interventions: ABP-671, Placebo; Drug · Other
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Breast Cancer
Interventions: Paclitaxel, BKM120 matching placebo, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more

Conditions: Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 40
States / cities: Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more

Conditions: Chronic Pain, Low Back Pain, Analgesia
Interventions: ALO-02, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 52
States / cities: Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more

Conditions: Chronic Heart Failure
Interventions: LCZ696, Valsartan, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more

Conditions: Ulcerative Colitis
Interventions: PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD, Placebo, PF-6826647 400 mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Canoga Park, California • Inglewood, California • Newport Beach, California + 12 more

Search by objective public record fields.

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Allergic Disease Onset Prevention Study

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

MPC-004 for the Treatment of an Acute Gout Flare

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis